Category: Abiomed Inc.
Here's a look at some of the top Wall Street stories for medical device companies this week: Asante Solutions sets IPO terms; Stryker CEO Lobo: M&A is our top priority for cash; Abiomed surges on Q3 numbers, FDA nod; Credit agencies lower Medtronic's rating post-Covidien merger
Abiomed shares surge to an all-time high after the heart pump maker crushes expectations with its fiscal 3rd-quarter results and raises its outlook for the rest of fiscal 2015.
Abiomed (NSDQ:ABMD) shares surged to an all-time high today after the heart pump maker crushed expectations for its fiscal 3rd quarter and raised its outlook on the rest of the year.
Abiomed wins a humanitarian device exemption for its Impella RP
Abiomed (NSDQ:ABMD) today said the FDA approved a humanitarian device exemption for its Impella RP heart pump, calling the device the 1st FDA-approved percutaneous, single-access pump for supporting the heart's right ventricle.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA warns Cook Medical on 'nonconformance' issues; Abiomed jumps on FDA deal for Impella indication; Hansen Medical launches 3rd-gen Sensei surgical robot; Medtronic wins EU nod for Resolute Onyx stent
Abiomed says it's come to an agreement with the FDA on an indication for its flagship Impella 2.5 heart pump, and now expects to win pre-market approval early next year without a hearing before an FDA advisory panel.
Medtronic taps Dr. Elizabeth Nabel, president of Brigham & Women's Faulkner Hospital in Boston, for a seat on its board of directors.
Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.